世界のデジタル病理市場予測及び動向（～2018）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 REPORT DESCRIPTION 19
1.3 MARKETS COVERED 20
1.4 STAKEHOLDERS 22
1.5 RESEARCH METHODOLOGY 23
1.5.1 SECONDARY RESEARCH 23
1.5.2 PRIMARY RESEARCH 25
1.5.3 KEY DATA FROM PRIMARY SOURCES 26
1.5.4 MARKET FORECAST 29
1.5.5 MARKET DATA VALIDATION AND DATA TRIANGULATION 31
1.6 ASSUMPTIONS 32
2 EXECUTIVE SUMMARY 33
3 MARKET OVERVIEW 37
3.1 MARKET DYNAMICS 37
3.1.1 DRIVERS 38
3.1.1.1 Rising prevalence of cancer 38
3.1.1.2 Improvement in lab efficiency 38
3.1.1.3 Drug development 38
3.1.1.4 Increasing use of companion diagnostics 39
3.1.1.5 Ease of consultation enabled by digital pathology 39
3.1.2 RESTRAINTS 40
3.1.2.1 High cost of digital pathology systems 40
3.1.2.2 Regulatory concerns 40
3.1.2.3 Conservative outlook of pathologists 40

3.1.3 OPPORTUNITIES 41
3.1.3.1 Digital pathology to help combat the shortage of pathologists 41
3.1.3.2 Affordable scanners for private pathology practices 41
3.1.3.3 Biopharmaceutical and drug toxicology studies 42
3.1.3.4 Personalized medicine 42
3.1.3.5 Digital pathology to aid collaborations between Asia and the west 42
3.2 MARKET SHARE ANALYSIS 43
3.2.1 DIGITAL PATHOLOGY MARKET, BY KEY PLAYER 43
3.3 INDUSTRY SPEAKS 47
4 DIGITAL PATHOLOGY: RATIONALE FOR ADOPTION 49
4.1 INTRODUCTION 50
4.2 SIGNIFICANCE OF DIGITAL PATHOLOGY 51
4.2.1 GEOGRAPHIC DISTRIBUTION OF PATHOLOGISTS 51
4.2.2 CASE TRANSPORT 51
4.2.3 CASE REVIEW 51
4.2.4 ADDITIONAL STUDIES 52
4.2.5 DIAGNOSIS ENTRY 52
4.2.6 QUALITY CONTROL 52
4.3 WHY A LAB SHOULD ADOPT THE DIGITAL PATHOLOGY TECHNOLOGY 53
5 GLOBAL DIGITAL PATHOLOGY MARKET, BY PRODUCT 59
5.1 INTRODUCTION 60
5.2 SCANNERS 62
5.3 ANALYTICS 64
5.3.1 VISUALIZATION SOFTWARE 64
5.3.2 DIGITAL PATHOLOGY INFORMATION MANAGEMENT SYSTEMS 64
5.3.3 IMAGE ANALYSIS PLATFORMS 64
5.4 STORAGE 66
5.5 COMMUNICATION/DELIVERY MODES 68
5.5.1 WEB-BASED 71
5.5.2 CLOUD-BASED 72
6 GLOBAL DIGITAL PATHOLOGY MARKET, BY APPLICATION 75
6.1 INTRODUCTION 76
6.2 HUMAN PATHOLOGY 78
6.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 80
6.2.2 HOSPITALS/REFERENCE LABORATORIES/ACADEMIC MEDICAL CENTERS (AMC) 81
6.2.3 TRAINING AND EDUCATION 83
6.3 ANIMAL PATHOLOGY 84
6.3.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 86
6.3.2 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 87
6.3.3 CONTRACT RESEARCH ORGANIZATIONS 89
7 GLOBAL DIGITAL PATHOLOGY MARKET, BY GEOGRAPHY 91
7.1 INTRODUCTION 92
7.2 NORTH AMERICA 94
7.2.1 U.S. 97
7.2.1.1 Favorable reimbursement scenario for digital pathology in the U.S. to boost the market 97
7.2.2 CANADA 99
7.2.2.1 Embracing digital pathology to improve the quality of healthcare in Canada 99
7.3 EUROPE 102
7.3.1 U.K. 106
7.3.1.1 Technological developments in the U.K. to propel the market 106
7.3.1.2 Conferences in the U.K. to boost the market 106
7.3.2 GERMANY 108
7.3.2.1 Conferences in Germany to trigger growth 108
7.3.3 ITALY 110
7.3.3.1 Successful digital pathology projects in Italy 110
7.3.4 FRANCE 112
7.3.4.1 Use of digital pathology in the pharmaceutical industry to boost the market in France 112

7.3.5 SPAIN 114
7.3.5.1 Adoption of digital pathology to improve quality of healthcare 114
7.3.6 DENMARK 116
7.3.6.1 Alarming rise in prevalence of cancer to boost the market in Denmark 116
7.3.7 NORWAY 118
7.3.7.1 Digital pathology revolution in Norway to propel market growth 118
7.3.8 SWEDEN 120
7.3.8.1 Conferences in Sweden to boost the market 120
7.3.8.2 Positive funding scenario in Sweden to focus on innovation 121
7.3.9 REST OF EUROPE (ROE) 122
7.3.9.1 Digital pathology gaining momentum in the Netherlands 122
7.4 ASIA 125
7.4.1 CHINA 128
7.4.1.1 Collaborations in China to boost market growth 128
7.4.1.2 Ministry of Health in China encourages use of digital pathology 128
7.4.2 JAPAN 130
7.4.2.1 Focus on stomach cancer diagnosis to propel the market in Japan 130
7.4.3 INDIA 132
7.4.3.1 Digital pathology gaining momentum in India 132
7.4.4 MIDDLE EAST 134
7.4.4.1 Exhibitions in the Middle East to increase awareness of digital pathology 134
7.4.5 REST OF ASIA (ROA) 136
7.4.5.1 Bilateral agreements aimed to increase awareness of digital pathology in Pakistan 136
7.5 REST OF THE WORLD (ROW) 139
7.5.1 LATIN AMERICA 142
7.5.1.1 Players eyeing Brazil as an attractive market 142

7.5.2 AFRICA 144
7.5.2.1 Strategies by key players to aid growth of digital pathology in Africa 144
7.5.3 RUSSIA 146
7.5.3.1 Increasing popularity of digital pathology as a cost-effective solution to help propel the market in Russia 146
7.5.4 PACIFIC COUNTRIES 148
7.5.4.1 Patients in Pacific countries to receive better and timely diagnosis due to digital pathology 148
8 COMPETITIVE LANDSCAPE 151
8.1 INTRODUCTION 151
8.2 NEW PRODUCT LAUNCHES 155
8.3 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 156
8.4 ACQUISITIONS 158
8.5 OTHER DEVELOPMENTS 159
9 COMPANY PROFILES 161
(Overview, Financials, Products & Services, Strategy, & Developments)*

9.1 3DHISTECH LTD. 161
9.2 APOLLO PACS, INC. 166
9.3 AURORA INTERACTIVE LTD. 171
9.4 CORISTA LLC 174
9.5 DEFINIENS AG 177
9.6 DIGIPATH INC. 182
9.7 HAMAMATSU PHOTONICS K.K. 186
9.8 HURON TECHNOLOGIES INTERNATIONAL, INC. 191
9.9 INDICA LABS, INC. 195
9.10 KANTERON SYSTEMS 199
9.11 LEICA BIOSYSTEMS, GMBH 202
9.12 LIGOLAB, LLC 208
9.13 MIKROSCAN TECHNOLOGIES, INC. 210
9.14 NIKON INSTRUMENTS, INC. 213
9.15 OBJECTIVE PATHOLOGY SERVICES, LTD. 216
9.16 OMNYX, LLC 218
9.17 XIFIN, INC. 222
9.18 PATHXL, LTD. 225
9.19 PIXCELLDATA, LTD. 231
9.20 SUNQUEST INFORMATION SYSTEMS, INC. 234
9.21 VENTANA MEDICAL SYSTEMS, INC. 238
9.22 VISIOPHARM 246

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.